Form D · Pharmaceuticals
OSPREY PHARMACEUTICALS USA INC
San Francisco, CA · CIK 0001436994
Offering snapshot reported May 20, 2009 · SEC filing
- Reported sold
- $5.89M Offering amount: $9.05M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 20, 2009 | Initial | $5,892,744 | No comparison | Not reported | SEC filing |
| Jun 3, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-118943
Source: Form D, filed May 20, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jack Anthony | Director, Executive |
| Barbara Finck | Executive |
| John Hamer | Director |
| Martial La Croix | Director |
| Jean Francois Pariseau | Director |
| Nassim Usman | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
425 California Street Suite 1300
San Francisco, CA, 94104
San Francisco, CA, 94104